every patient with IIIA-N2 NSCLC. We concur with the editorial that patients who are good candidates for surgery may still be appropriately managed by using resection rather than radiation. 6 We should continue to pursue further improvement in the current 5-year survival prospects of approximately 30% with surgical multimodality treatment for resectable N2, by integration of modern techniques such as positron emission tomography-computed tomography, videomediastinoscopy, and ultrasound-guided endoscopy into a truly multidisciplinary process of staging and assessment of resectability. 7, 8 Furthermore, answers from ongoing trials on the question whether modern chemoradiotherapy induction may be superior to chemotherapy are eagerly awaited.
